Ligand Pharmaceuticals Incorporated LGND R2K
Company Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Why Investors Should Care
Generates a return on equity of 17.1%, reflecting efficient use of shareholder capital.
Revenue has grown at a 12.8% CAGR over the past five years.
Maintains a net profit margin of 55.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $268.09M (+60.4% YoY); net profit $124.45M.
- Trailing 12 Months Year-on-year growth — revenue +14.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.82% |
| 1 Year: | 14.10% |
Stock Price Performance
| 1 Year: | +137.13% |
| 6 Months: | +45.64% |
| 3 Months: | +41.01% |
| 1 Month: | +18.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.35 · Neutral
P/E of 39.19 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 55.9%.
- Compounding revenue at 12.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LGND Ligand Pharmaceuticals Incorporated R2K | 300.97 | 39.19 | $6.03B | 0.00% | 2.69% | 17.13% | 12.82% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 56.16M | 90.04M | 45.66M | 59.59M | 56.16M | 90.04M | 45.66M | 59.59M | 43.48M | 24.99M | 24.81M | 27.00M | 33.16M | 41.42M | 41.85M | 69.99M | 46.59M | 78.85M | 59.69M | 56.40M | 36.52M | 50.13M | 59.22M | 50.38M | 43.98M | 26.37M | 32.87M | 30.98M | 41.53M | 51.81M | 45.33M | 47.63M | 115.46M | 51.72M |
| Operating Income | 8.60M | - | 15.10M | 3.97M | 5.47M | - | 10.22M | 13.02M | 16.49M | - | 37.04M | 70.17M | 23.36M | - | 826.54M | -4.13M | -5.16M | - | 3.79M | 7.10M | 3.75M | - | 4.71M | 45.74M | 15.71M | - | 2.13M | 8.66M | 12.34M | - | 14.21M | -1.98M | 3.08M | 2.99M | -19.10M | 3.14M | -36.22M | 8.44M | 54.93M | 17.37M |
| Net Income | 199.16M | 6.34M | 6.61M | -6.17M | 1.05M | -3.12M | 45.28M | 73.16M | 67.36M | -42.48M | 45.28M | 73.16M | 67.36M | -42.48M | 666.34M | -14.42M | -15.25M | -7.37M | -24.13M | 22.09M | -6.70M | 5.76M | 18.11M | 30.73M | 13.72M | -5.42M | -15.38M | -895.00K | 404.00K | -17.48M | 41.95M | 2.29M | -10.27M | 86.14M | -51.91M | -7.17M | -42.45M | 4.85M | 117.27M | -13.35M |
| Diluted EPS | 9.28 | 0.29 | 0.30 | -0.30 | 0.05 | 0.15 | 1.83 | 2.99 | 2.80 | -2.02 | 1.83 | 2.99 | 2.80 | -2.02 | 31.32 | -0.74 | -0.81 | -0.43 | -1.46 | 1.32 | -0.42 | 0.35 | 1.05 | 1.79 | 0.80 | - | -0.91 | -0.05 | 0.02 | - | 2.33 | 0.13 | -0.59 | 4.75 | -2.88 | -0.39 | -2.21 | 0.24 | 5.68 | -0.67 |
| R&D Expense | 1.95M | - | 4.00M | 4.91M | 5.90M | - | 8.67M | 4.82M | 4.76M | - | 7.41M | 6.13M | 5.48M | - | 11.29M | 12.21M | 13.74M | - | 11.89M | 12.73M | 12.85M | - | 9.05M | 7.48M | 7.43M | 8.15M | 9.18M | 8.47M | 9.24M | 9.20M | 6.66M | 6.85M | 5.53M | 5.97M | 5.35M | 5.67M | 50.09M | 6.57M | 21.02M | 2.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.94M | 23.54M | 30.04M | 31.39M | 48.97M | 64.54M | 71.91M | 108.97M | 141.10M | 251.45M | 120.28M | 163.56M | 241.54M | 196.25M | 131.31M | 167.13M | 268.09M |
| Operating Income | -9.97M | -29.30M | -878.00K | 193.00K | 14.94M | 19.63M | 27.33M | 43.88M | 68.08M | 163.73M | 807.08M | 37.50M | 103.85M | 3.04M | 11.94M | -22.61M | 41.00M |
| Net Income | -1.95M | -10.37M | 9.71M | -527.00K | 11.42M | 12.02M | 229.82M | -1.64M | 12.56M | 143.32M | 629.30M | -2.98M | 57.14M | -33.36M | 52.15M | -4.03M | 124.45M |
| Diluted EPS | - | - | 0.49 | -0.03 | 0.55 | 0.56 | 10.83 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 | 6.13 |
| R&D Expense | 39.87M | 22.07M | 10.29M | 10.79M | 9.27M | 9.75M | 11.01M | 21.22M | 26.89M | 27.86M | 55.91M | 40.50M | 32.10M | 36.08M | 24.54M | 21.43M | 81.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 75.56M | 120.58M | 104.26M | 104.71M | 258.03M | 503.06M | 601.59M | 671.02M | 1.26B | 1.49B | 1.36B | 1.30B | 762.67M | 787.22M | 941.77M | 1.56B |
| Total Equity | -10.37M | 3.74M | -4.85M | 8.19M | 26.48M | 49.61M | 26.32M | 237.28M | 341.29M | 399.79M | 560.91M | 767.23M | 709.52M | 821.16M | 597.49M | 700.91M | 830.44M | 1.02B |
| Cash & Equivalents | 28.75M | 16.03M | 3.35M | 7.04M | 12.38M | 11.64M | 160.20M | 97.43M | 18.75M | 20.62M | 117.16M | 71.54M | 47.62M | 19.52M | 45.01M | 22.95M | 72.31M | 174.93M |
| Long Term Debt | - | - | - | - | 27.50M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 72.06M | 104.05M | 77.78M | 55.10M | 233.62M | 226.15M | 230.73M | 252.37M | 699.89M | 727.68M | 652.76M | 476.43M | 165.18M | 86.30M | 111.33M | 543.42M |
| Current Liabilities | - | - | 33.49M | 43.64M | 35.44M | 28.94M | 22.78M | 222.82M | 227.13M | 238.87M | 82.25M | 17.00M | 100.11M | 41.66M | 98.81M | 16.78M | 37.11M | 37.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -33.80M | -27.07M | -1.17M | 161.00K | 20.69M | 20.57M | 41.73M | 60.73M | 88.57M | 194.06M | -29.34M | 54.59M | 78.80M | 137.85M | 49.58M | 97.05M | 49.36M |
| Investing Cash Flow | 24.77M | 14.54M | -25.13M | 1.26M | -4.97M | -2.03M | -112.86M | -134.41M | -79.18M | -423.27M | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M | -143.66M | -377.32M |
| Financing Cash Flow | -3.69M | -159.00K | 30.00M | 3.92M | -16.46M | 130.03M | 8.36M | -4.99M | -7.52M | 328.58M | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M | 97.14M | 428.22M |
| Capital Expenditure | -522.00K | -70.00K | -78.00K | -595.00K | -377.00K | -6.00K | -93.00K | -1.85M | -2.16M | -887.00K | -2.55M | -4.46M | -8.76M | -17.92M | -3.52M | -1.82M | -452.00K |
| Free Cash Flow | -34.32M | -27.14M | -1.25M | -434.00K | 20.31M | 20.56M | 41.63M | 58.88M | 86.41M | 193.17M | -31.89M | 50.13M | 70.04M | 119.93M | 46.06M | 95.23M | 48.91M |
| Share Buybacks | - | 91.00K | 55.00K | 0 | 0 | 67.95M | 489.00K | 3.90M | 1.97M | 122.87M | 453.05M | 78.00M | 0 | 0 | 0 | 0 | 15.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -25.6% | -124.5% | -2.9% | 0.6% | 30.5% | 30.4% | 38.0% | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 15.3% |
| Net Margin % | -5.0% | -44.1% | 32.3% | -1.7% | 23.3% | 18.6% | 319.6% | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
| ROE % | -52.0% | 213.9% | 118.7% | -2.0% | 23.0% | 45.7% | 96.9% | -0.5% | 3.1% | 25.6% | 82.0% | -0.4% | 7.0% | -5.6% | 7.4% | -0.5% | 12.2% |
| ROCE % | - | -69.7% | -1.1% | 0.3% | 19.7% | 8.3% | 9.8% | 11.7% | 15.8% | 13.9% | 54.6% | 3.0% | 8.3% | 0.5% | 1.6% | -2.5% | 2.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.78% | 2.96M | $944.82M |
| 2 | Vanguard Portfolio Management LLC | 5.49% | 1.10M | $350.97M |
| 3 | Janus Henderson Group PLC | 5.04% | 1.01M | $322.15M |
| 4 | Vanguard Capital Management LLC | 4.23% | 848.09K | $270.53M |
| 5 | Invesco Ltd. | 4.11% | 823.60K | $262.72M |
| 6 | State Street Corporation | 3.89% | 778.86K | $248.45M |
| 7 | FMR, LLC | 2.97% | 596.13K | $190.16M |
| 8 | Franklin Resources, Inc. | 2.86% | 573.18K | $182.84M |
| 9 | Nomura Asset Management International Inc | 2.86% | 573.31K | $182.88M |
| 10 | Chicago Capital, LLC | 2.80% | 561.67K | $179.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LGND
Ligand’s Portfolio Now Tops 200 Biopharmaceutical Royalty Assets - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcTBHWFJ3d25VTVZ3M2JScUhyTkIxZnZvTE02eDFOcXV3MTh2VS1DaVdRT1oyUlRpMnZCdFVhWm9TYm1yV1p5TXBMMHVoZ1pmUFoyYmhLbDB3SUJYYXVJeng2dE5zRlVWYmYydTRFSmFsVUNYZ2Rsbzd5eDJRSXFBdVNKTWdCQ1VQbS1TOD…
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPaEgyck9rUWYzOG8tSnd1aktJZzRCTnQ3LVN4N2hMdzNTSUpaSXk4Tk9rd01femR2VmpDZWZpWkhSTzdoLXJpQ0ROTjB4MXEwbWkwMHpoYVM0N3hSbzFvOUNPVk5SMS1ES1N1bkowRUc5ZFBpMkM5YVZCSDZaRWQ1ZWJLa3o0dVc0ZUcxeT…
Ligand completes $739M acquisition of XOMA Royalty Corporation - Investing.com
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPbUxmQlNtVW9IaGdoY2NXakM0YjNDN3Vsa056VzJTNDU2d0xoNWlUcV9jQTItQnlQbjA4RDlqQ01ReXJQWmhqTUNsb2o3OXoyTWNEaU9hejR2d2xIZWloMHBXZmhHQmF5UnhaZG5CdG5PRVdpRmc1ME1sS0xfaHQ0SXhyOTYtX01QbXZpUW…
3 Overlooked Stocks Positioned for the Next Market Rotation - MarketBeat
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPRFUxMTkySk5vX0ZiMWZacGdMd0R5eTR2WFFXNVYyc3BWZ3JWcFQyWHVYcVo0bU5xT0xyV2cySDkwcU5LbU1NZ2VvbVlqQmhNMGpicHZ5WkNPM0NNVWpyYWJqMlVTcnZXRm9QS1Q0eEFPOVQxTjNSemFqcU1Ic2xxdS1GTHFoSlJpdEJXbE…
LGND Stock Draws Traders As Royalties Rise, Debt Deal Hits - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOMXB0eFlyM2JoemRJU0ZhVVowcVZoLVU5aU5wc0xPSG51ZGI1REN0TEVibE5jMFBKZlZtUGJ0YjZxbC1xQlJaTV9mRXlRaFVITGJFWUNXUGVsVHZ0R3BVSlBqdUtZdVRJU1plNUZQTFpJcklqUS1uV0NBQ2N1VEdoQTNWcEp3WWVteG9LSn…
LGND Maintained by B of A Securities -- Price Target Raised to $388 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNMWdTdXhST252cXRvc09OX3BMTkozX0hDekUxLVlna1JKVV9LWnJMemtmbWE4eFE3T0x4Skc3eTF5U3RQMHI2TU1jaHFFbkNmYU1xZld3alhXZEhuVE14NGNlS054MjJwTWV6WHdaTWpOaDdZWlhxakNhclFqdjgyRFpua0ZjQm1xRnFXYl…
LGND — Frequently Asked Questions
What is the current share price of Ligand Pharmaceuticals Incorporated (LGND)?
As of 2026-07-14 21:23 PDT, Ligand Pharmaceuticals Incorporated (LGND) trades at $300.97 on NasdaqGM. Its 52-week range is $124.30 to $322.61.
What is the market capitalisation of LGND?
Ligand Pharmaceuticals Incorporated (LGND) has a market capitalisation of $6.03B on NasdaqGM.
What is the P/E ratio of LGND?
LGND trades at a trailing price-to-earnings (P/E) ratio of 39.19. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.13.
What is the return on equity (ROE) of LGND?
LGND has a return on equity (ROE) of 17.13%. Its return on capital employed (ROCE) is 2.69%.
Is LGND a good stock to buy?
This page provides a data-driven analysis of Ligand Pharmaceuticals Incorporated (LGND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.